STOCK TITAN

GILEAD SCIENCES (GILD) SEC Filings

GILD NASDAQ

Gilead Sciences filings document material events, operating results, governance matters and capital-structure disclosures for a Delaware biopharmaceutical company whose common stock trades as GILD on the Nasdaq Global Select Market. Form 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP measures and reconciliations, and disclose completed acquisition activity affecting oncology pipeline assets.

Proxy and annual meeting filings record director elections, auditor ratification and shareholder voting outcomes. Other current reports cover executive and governance changes, Regulation FD disclosures, material agreements, and formal exhibits tied to Gilead’s virology and oncology business, including clinical or regulatory disclosure categories when they are part of the company’s public reporting.

Rhea-AI Summary

Gilead Sciences, Inc. Chief Comm & Corp Aff Officer Johanna Mercier exercised options on November 16, 2026, to acquire 25,000 common shares at $72.34 and sold 28,000 shares in three reported transactions that day. Sale prices ranged from $169.57 to $170.56 for 13,922 shares, $170.58 to $171.53 for 13,178 shares, and $171.65 to $171.69 for 900 shares. The transactions were made under a Rule 10b5-1 trading plan adopted February 20, 2025. Following the option transaction, her reported option position was 44,960 options. The options have a four-year vesting schedule: 25% vest on the grant’s first anniversary, with the balance vesting 6.25% quarterly thereafter until fully vested.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Gilead Sciences, Inc. (GILD) Chief Financial Officer Andrew D. Dickinson sold 3,000 shares of common stock at $171.47 per share on November 16, 2026. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. After the transaction, Dickinson directly held 158,096 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Gilead Sciences, Inc. (GILD) officer Andrew Dickinson gave notice of a proposed sale of 3,000 common shares, with an aggregate market value of $514,410 and an approximate sale date of November 16, 2026. Morgan Stanley Smith Barney LLC is named as broker. The stated Rule 10b5-1 plan adoption or instruction date is August 29, 2024. Dickinson acquired 3,000 performance shares from Gilead on January 31, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

Gilead Sciences, Inc. officer Johanna Mercier gave notice of a proposed sale of 28,000 common shares, with an approximate sale date of November 16, 2026 and aggregate market value of $4,775,527.25. The securities information lists 3,000 performance shares acquired February 4, 2025 and 25,000 shares from a cash stock-option exercise dated November 16, 2026.

The notice lists February 20, 2025 as the plan adoption or instruction date if relying on Rule 10b5-1. It also reports three common-stock sales during the preceding three months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Gilead Sciences, Inc. (GILD) director Kelly A. Kramer exercised 10,376 non-qualified stock options on November 12, 2026, at an exercise price of $66.92 per share, acquiring 10,376 common shares. Kramer reported sales of 10,376 common shares that day in four transactions: 1,676 at $168.2255, 3,800 at $169.4423, 4,700 at $170.4941 and 200 at $171.44 per share. The transactions were made under a Rule 10b5-1 trading plan adopted August 13, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.30%
Tags
insider
-
Rhea-AI Summary

Kelly Kramer, a director of Gilead Sciences, Inc. (GILD), filed notice of a proposed sale of 10,376 common shares, with an aggregate market value of $1,761,118.48. The notice lists an approximate sale date of November 12, 2026. Kramer acquired the shares by exercising stock options and paying cash; the notice lists August 13, 2026 as the Rule 10b5-1 plan adoption or instruction date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
other
Rhea-AI Summary

Gilead Sciences, Inc. officer Wettan Keeley M. Cain, identified as EVP Gen Counsel, Legal & Comp, sold 3,399 shares of Common Stock at $164.11 per share on November 6, 2026, under a Rule 10b5-1 trading plan adopted on August 7, 2026. His reported direct holdings after the sale were 5,360 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
insider
-
Rhea-AI Summary

Gilead Sciences, Inc. Chairman & CEO Daniel Patrick O’Day exercised options for 102,619 shares on November 4, 2026, at a $72.34 exercise price, and sold the same number of shares that day at a reported $175.1627 per share. On November 5, he exercised options for 9,810 shares at $72.34 and sold the same number at a reported $175.17 per share. The transactions were made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
insider
-
Rhea-AI Summary

Gilead Sciences, Inc. (GILD) officer Keeley M. Cain Wettan reported a proposed sale of 3,399 common shares, with an aggregate market value of $569,570.43 and an approximate sale date of November 6, 2026. The shares were acquired upon vesting of restricted stock units from August 10 through September 10, 2026, and Morgan Stanley Smith Barney LLC is listed as the broker.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
other
Rhea-AI Summary

Gilead Sciences (GILD), acting as an institutional investment manager, reported a Form 13F holdings report with 5 information-table entries and a reported value total of $1,463,841,605, rounded to the nearest dollar. The report lists Gilead Therapeutics A1 Unlimited Co as 1 other included manager.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
other

FAQ

How many GILEAD SCIENCES (GILD) SEC filings are available on StockTitan?

StockTitan tracks 184 SEC filings for GILEAD SCIENCES (GILD), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for GILEAD SCIENCES (GILD)?

The most recent SEC filing for GILEAD SCIENCES (GILD) was filed on November 17, 2026.